Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 198 clinical trials
Prophylactic Anticoagulation for Catheter-related Thrombosis

The main objective of this study is to compare the efficacy and safety of aspirin, low molecule heparin and rivaroxaban for preventing catheter-related thrombosis in middle-to-high-risk

  • 0 views
  • 25 Jan, 2021
  • 19 locations
Calcium Administration in Cardiac Surgery

heparin, albumin and citrate. Perioperative hypocalcemia is often complicated by development of arrhythmias, especially QT interval prolongation. Furthermore, low content of calcium can lead to vascular

cardiopulmonary bypass
heparin
bypass surgery
heart surgery
reperfusion injury
  • 21 views
  • 28 Jan, 2021
  • 11 locations
Pregnancy and Risk of Venous Thromboembolism

individual basis with regard to lowering the absolute risk of thrombosis, the inconvenience of daily subcutaneous heparin therapy and the potential risks of bleeding, heparin-induced thrombocytopenia and

  • 0 views
  • 28 Jan, 2021
Extended Peri-operative Tinzaparin to Improve Disease-free Survival in Patients With Resectable Colorectal Cancer

heparin" (LMWH) can suppress the development of metastases after surgery in animal experiments. The investigators want to see if giving patients with colorectal cancer the blood thinner, LMWH, around the

metastasis
tinzaparin
low molecular weight heparin
cancer
ct scan
  • 119 views
  • 24 Jan, 2021
  • 17 locations
Thromboembolic Risk Stratification by TRiP(Cast) Score to Guide Physicians in Preventive Treatment Prescriptions for Patients With Lower Limb Trauma Requiring Brace or castING.

randomised controlled study on the subject did not show the benefit of low-molecular-weight heparin (LMWH) on the rate of symptomatic VTE among 1,435 non-selected patients. Therefore, in 2017, the Cochrane

  • 0 views
  • 05 Mar, 2021
  • 13 locations
ACT Guided Heparinization During Open Abdominal Aortic Aneurysm Repair.

Aim of the ACTION-1 study is to determine whether ACT guided heparinization decreases thrombo-embolic complications (TEC) and mortality after elective open AAA surgery, without causing more bleeding complications.

aneurysm repair
heparin
aortic aneurysm
aaa surgery
open repair
  • 10 views
  • 28 Jan, 2021
  • 18 locations
Hokusai Study in Pediatric Patients With Confirmed Venous Thromboembolism (VTE)

This is an event driven Phase 3, prospective, randomized, open-label, blinded endpoint evaluation (PROBE) parallel group study in subjects with confirmed VTE. This study is designed to evaluate the pharmacokinetics (PK) and pharmacodynamics (PD) of edoxaban and to compare the efficacy and safety of edoxaban against standard of care in …

heparin
edoxaban
anticoagulants
probe
anticoagulant therapy
  • 0 views
  • 28 Jan, 2021
  • 170 locations
Comparison of Bleeding Risk Between Rivaroxaban and Apixaban for the Treatment of Acute Venous Thromboembolism

Apixaban and rivaroxaban have been compared to standard therapy for treatment of acute symptomatic venous thromboembolism (VTE) in randomized controlled trials (RCTs), and are both approved by Health Canada. No safety or efficacy data is available from direct head-to-head comparison of these two anticoagulants. Lawsuits in the United States over …

probe
apixaban
venous thromboembolism
rivaroxaban
anticoagulants
  • 285 views
  • 29 Jan, 2021
  • 21 locations
FREEDOM COVID-19 Anticoagulation Strategy

Coronavirus Disease (COVID-19), caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), has led to unprecedented morbidity and mortality in the modern era. To date, nearly 13 million people have contracted COVID-19, leading to more than 550,000 deaths worldwide. As the number of affected individuals continues to climb, effective strategies for …

acute respiratory distress
lymphopenia
SARS
angiotensin
enoxaparin
  • 20 views
  • 19 Feb, 2021
  • 20 locations
API-CAT STUDY for APIxaban Cancer Associated Thrombosis

The main objective is to determine whether a low-dose regimen of apixaban (2.5 mg bid) is non inferior to a full-dose regimen of apixaban (5 mg bid) for the prevention of recurrent venous thromboembolism (VTE) in patients with active cancer who have completed at least 6 months of anticoagulant therapy …

  • 8 views
  • 03 Mar, 2021
  • 120 locations